Clinical Trial Update: Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluates Galinpepimut-S as maintenance therapy versus investigator's choice of best available therapy in acute myeloid leukemia patients in CR2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Galinpepimut-S

Snippet

Sponsor: Sellas Life Sciences Group | Conditions: Acute Myeloid Leukemia | Phase 3 | Status: ACTIVE_NOT_RECRUITING